NVS catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 23, 2026Sponsor estimate | NCT05399992Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVDNovartis Pharmaceuticals · Primary Hypercholesterolemia | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT05703516A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaNovartis Pharmaceuticals · Non-Small-Cell Lung Carcinoma | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07821411A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and JapanNovartis Pharmaceuticals · Multiple Sclerosis | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 23, 2026Sponsor estimateNo phase registeredNCT05399992Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVDNovartis Pharmaceuticals · Primary HypercholesterolemiaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT05703516A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaNovartis Pharmaceuticals · Non-Small-Cell Lung CarcinomaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07821411A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and JapanNovartis Pharmaceuticals · Multiple SclerosisActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 3, 2026Sponsor estimate | NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive...Novartis Pharmaceuticals · Metastatic Hormone-sensitive Prostate Cancer | NVSLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Dec 15, 2026Sponsor estimate | NCT06092879Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in...Novartis Pharmaceuticals · Chronic Myeloid Leukemia | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Dec 16, 2026Sponsor estimate | NCT05776888Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 YearsNovartis Pharmaceuticals · Relapsing Multiple Sclerosis | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 3, 2026Sponsor estimatePhase 2NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive...Novartis Pharmaceuticals · Metastatic Hormone-sensitive Prostate CancerActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimateNo phase registeredNCT06092879Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in...Novartis Pharmaceuticals · Chronic Myeloid LeukemiaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2026Sponsor estimateNo phase registeredNCT05776888Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 YearsNovartis Pharmaceuticals · Relapsing Multiple SclerosisActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.